Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental cancer cocktails show promise, but study halted early

NCT ID NCT04000529

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested two drug combinations—TNO155 plus spartalizumab or ribociclib—in 122 adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The goal was to check safety and see if the drugs could slow cancer growth. The study was terminated, so full results are not available, but the data may guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

TNO155 (a drug) combined with either spartalizumab (an immunotherapy) or ribociclib (a targeted therapy)

What this could lead to

If successful, this could point toward new combination treatments for several advanced cancers, including lung, head and neck, and colorectal cancers.

What could go wrong

This was a very early (Phase 1) study that was terminated, so results are limited. The combinations may cause significant side effects or fail to shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 colorectal cancer colorectal neoplasm esophageal squamous cell carcinoma gastrointestinal stromal tumor head and neck squamous cell carcinoma non-small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER ESOPHAGEAL SCC GASTROINTESTINAL STROMAL TUMORS HEAD AND NECK SQUAMOUS CELL CARCINOMA NON SMALL CELL LUNG CARCINOMA

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Novartis Investigative Site

    Westmead, New South Wales, 2145, Australia

  • Novartis Investigative Site

    Brussels, 1200, Belgium

  • Novartis Investigative Site

    Chengdu, Sichuan, 610041, China

  • Novartis Investigative Site

    Cologne, 50937, Germany

  • Novartis Investigative Site

    Hong Kong, Hong Kong

  • Novartis Investigative Site

    Chuo Ku, Tokyo, 104 0045, Japan

  • Novartis Investigative Site

    Singapore, 119228, Singapore

  • Novartis Investigative Site

    Barcelona, Catalonia, 08035, Spain

  • Novartis Investigative Site

    Valencia, Valencia, 46010, Spain